nodes	percent_of_prediction	percent_of_DWPC	metapath
Cilostazol—CYP3A5—Beclomethasone—psoriasis	0.0733	0.102	CbGbCtD
Cilostazol—CYP1A2—Clobetasol propionate—psoriasis	0.072	0.1	CbGbCtD
Cilostazol—CYP1A2—Methoxsalen—psoriasis	0.0378	0.0526	CbGbCtD
Cilostazol—CYP2D6—Hydroxyurea—psoriasis	0.0341	0.0474	CbGbCtD
Cilostazol—CYP3A7—Hydrocortisone—psoriasis	0.0312	0.0434	CbGbCtD
Cilostazol—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0312	0.0434	CbGbCtD
Cilostazol—CYP3A7—Cyclosporine—psoriasis	0.0295	0.041	CbGbCtD
Cilostazol—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0295	0.041	CbGbCtD
Cilostazol—CYP3A5—Mycophenolate mofetil—psoriasis	0.0292	0.0406	CbGbCtD
Cilostazol—CYP2C19—Cholecalciferol—psoriasis	0.0272	0.0378	CbGbCtD
Cilostazol—CYP3A4—Calcitriol—psoriasis	0.0255	0.0354	CbGbCtD
Cilostazol—CYP3A5—Hydrocortisone—psoriasis	0.0234	0.0326	CbGbCtD
Cilostazol—CYP3A5—Cyclosporine—psoriasis	0.0221	0.0308	CbGbCtD
Cilostazol—CYP2D6—Cholecalciferol—psoriasis	0.0207	0.0287	CbGbCtD
Cilostazol—CYP3A4—Methoxsalen—psoriasis	0.0198	0.0276	CbGbCtD
Cilostazol—CYP3A7—Dexamethasone—psoriasis	0.0194	0.027	CbGbCtD
Cilostazol—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0194	0.027	CbGbCtD
Cilostazol—CYP2C19—Prednisone—psoriasis	0.0188	0.0262	CbGbCtD
Cilostazol—CYP2C19—Cyclosporine—psoriasis	0.0178	0.0248	CbGbCtD
Cilostazol—CYP3A5—Dexamethasone—psoriasis	0.0146	0.0203	CbGbCtD
Cilostazol—CYP2D6—Cyclosporine—psoriasis	0.0136	0.0189	CbGbCtD
Cilostazol—CYP3A4—Cholecalciferol—psoriasis	0.0131	0.0183	CbGbCtD
Cilostazol—CYP2C19—Dexamethasone—psoriasis	0.0118	0.0163	CbGbCtD
Cilostazol—CYP3A4—Mycophenolate mofetil—psoriasis	0.0114	0.0158	CbGbCtD
Cilostazol—CYP3A4—Triamcinolone—psoriasis	0.0114	0.0158	CbGbCtD
Cilostazol—CYP3A4—Betamethasone—psoriasis	0.00977	0.0136	CbGbCtD
Cilostazol—CYP3A4—Prednisolone—psoriasis	0.00964	0.0134	CbGbCtD
Cilostazol—CYP3A4—Hydrocortisone—psoriasis	0.00914	0.0127	CbGbCtD
Cilostazol—CYP3A4—Prednisone—psoriasis	0.0091	0.0127	CbGbCtD
Cilostazol—CYP2D6—Dexamethasone—psoriasis	0.00894	0.0124	CbGbCtD
Cilostazol—CYP3A4—Cyclosporine—psoriasis	0.00863	0.012	CbGbCtD
Cilostazol—CYP3A4—Dexamethasone—psoriasis	0.00568	0.0079	CbGbCtD
Cilostazol—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.000932	0.0673	CbGpPWpGaD
Cilostazol—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000841	0.0606	CbGpPWpGaD
Cilostazol—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000773	0.0558	CbGpPWpGaD
Cilostazol—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000721	0.052	CbGpPWpGaD
Cilostazol—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000674	0.0486	CbGpPWpGaD
Cilostazol—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000521	0.0376	CbGpPWpGaD
Cilostazol—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000479	0.0346	CbGpPWpGaD
Cilostazol—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000406	0.0293	CbGpPWpGaD
Cilostazol—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000387	0.0279	CbGpPWpGaD
Cilostazol—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000382	0.0276	CbGpPWpGaD
Cilostazol—PDE3A—Nitric oxide stimulates guanylate cyclase—NOS2—psoriasis	0.00037	0.0267	CbGpPWpGaD
Cilostazol—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000314	0.0226	CbGpPWpGaD
Cilostazol—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000313	0.0226	CbGpPWpGaD
Cilostazol—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00028	0.0202	CbGpPWpGaD
Cilostazol—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000276	0.0199	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—SERPINB8—psoriasis	0.000271	0.0195	CbGpPWpGaD
Cilostazol—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000227	0.0164	CbGpPWpGaD
Cilostazol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000216	0.0156	CbGpPWpGaD
Cilostazol—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000214	0.0154	CbGpPWpGaD
Cilostazol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000199	0.0144	CbGpPWpGaD
Cilostazol—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000196	0.0142	CbGpPWpGaD
Cilostazol—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000175	0.0127	CbGpPWpGaD
Cilostazol—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000169	0.0122	CbGpPWpGaD
Cilostazol—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000167	0.012	CbGpPWpGaD
Cilostazol—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000166	0.012	CbGpPWpGaD
Cilostazol—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000164	0.0119	CbGpPWpGaD
Cilostazol—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000161	0.0116	CbGpPWpGaD
Cilostazol—PDE3A—Platelet homeostasis—NOS2—psoriasis	0.000144	0.0104	CbGpPWpGaD
Cilostazol—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000137	0.00986	CbGpPWpGaD
Cilostazol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00013	0.00938	CbGpPWpGaD
Cilostazol—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000128	0.00926	CbGpPWpGaD
Cilostazol—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000121	0.00869	CbGpPWpGaD
Cilostazol—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000119	0.00857	CbGpPWpGaD
Cilostazol—Vertigo—Dexamethasone—psoriasis	0.00011	0.000412	CcSEcCtD
Cilostazol—Vertigo—Betamethasone—psoriasis	0.00011	0.000412	CcSEcCtD
Cilostazol—Syncope—Betamethasone—psoriasis	0.00011	0.000411	CcSEcCtD
Cilostazol—Syncope—Dexamethasone—psoriasis	0.00011	0.000411	CcSEcCtD
Cilostazol—Pain—Mycophenolate mofetil—psoriasis	0.00011	0.000411	CcSEcCtD
Cilostazol—Infection—Triamcinolone—psoriasis	0.000109	0.00041	CcSEcCtD
Cilostazol—Hypotension—Hydrocortisone—psoriasis	0.000109	0.000409	CcSEcCtD
Cilostazol—Haematuria—Methotrexate—psoriasis	0.000109	0.000407	CcSEcCtD
Cilostazol—Feeling abnormal—Cyclosporine—psoriasis	0.000108	0.000406	CcSEcCtD
Cilostazol—Shock—Triamcinolone—psoriasis	0.000108	0.000406	CcSEcCtD
Cilostazol—Insomnia—Prednisolone—psoriasis	0.000108	0.000406	CcSEcCtD
Cilostazol—Hepatobiliary disease—Methotrexate—psoriasis	0.000108	0.000404	CcSEcCtD
Cilostazol—Gastrointestinal pain—Cyclosporine—psoriasis	0.000108	0.000403	CcSEcCtD
Cilostazol—Loss of consciousness—Dexamethasone—psoriasis	0.000108	0.000403	CcSEcCtD
Cilostazol—Loss of consciousness—Betamethasone—psoriasis	0.000108	0.000403	CcSEcCtD
Cilostazol—Dizziness—Mycophenolic acid—psoriasis	0.000108	0.000403	CcSEcCtD
Cilostazol—Epistaxis—Methotrexate—psoriasis	0.000107	0.000403	CcSEcCtD
Cilostazol—Paraesthesia—Prednisolone—psoriasis	0.000107	0.000403	CcSEcCtD
Cilostazol—Tachycardia—Triamcinolone—psoriasis	0.000107	0.000402	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000106	0.000399	CcSEcCtD
Cilostazol—Agranulocytosis—Methotrexate—psoriasis	0.000106	0.000398	CcSEcCtD
Cilostazol—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000106	0.000396	CcSEcCtD
Cilostazol—Insomnia—Hydrocortisone—psoriasis	0.000106	0.000396	CcSEcCtD
Cilostazol—Hypertension—Betamethasone—psoriasis	0.000106	0.000396	CcSEcCtD
Cilostazol—Hypertension—Dexamethasone—psoriasis	0.000106	0.000396	CcSEcCtD
Cilostazol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000105	0.00761	CbGpPWpGaD
Cilostazol—Paraesthesia—Hydrocortisone—psoriasis	0.000105	0.000393	CcSEcCtD
Cilostazol—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000105	0.000393	CcSEcCtD
Cilostazol—Urticaria—Cyclosporine—psoriasis	0.000104	0.000391	CcSEcCtD
Cilostazol—Myalgia—Betamethasone—psoriasis	0.000104	0.00039	CcSEcCtD
Cilostazol—Myalgia—Dexamethasone—psoriasis	0.000104	0.00039	CcSEcCtD
Cilostazol—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000104	0.00751	CbGpPWpGaD
Cilostazol—Body temperature increased—Cyclosporine—psoriasis	0.000104	0.000389	CcSEcCtD
Cilostazol—Abdominal pain—Cyclosporine—psoriasis	0.000104	0.000389	CcSEcCtD
Cilostazol—Anxiety—Dexamethasone—psoriasis	0.000104	0.000389	CcSEcCtD
Cilostazol—Anxiety—Betamethasone—psoriasis	0.000104	0.000389	CcSEcCtD
Cilostazol—PDE3A—GPCR downstream signaling—HCAR2—psoriasis	0.000104	0.00748	CbGpPWpGaD
Cilostazol—Vomiting—Mycophenolic acid—psoriasis	0.000103	0.000387	CcSEcCtD
Cilostazol—Discomfort—Dexamethasone—psoriasis	0.000103	0.000386	CcSEcCtD
Cilostazol—Discomfort—Betamethasone—psoriasis	0.000103	0.000386	CcSEcCtD
Cilostazol—Dyspepsia—Hydrocortisone—psoriasis	0.000103	0.000385	CcSEcCtD
Cilostazol—Haemoglobin—Methotrexate—psoriasis	0.000103	0.000385	CcSEcCtD
Cilostazol—Rash—Mycophenolic acid—psoriasis	0.000103	0.000384	CcSEcCtD
Cilostazol—Dermatitis—Mycophenolic acid—psoriasis	0.000102	0.000384	CcSEcCtD
Cilostazol—Pain—Prednisolone—psoriasis	0.000102	0.000383	CcSEcCtD
Cilostazol—Haemorrhage—Methotrexate—psoriasis	0.000102	0.000383	CcSEcCtD
Cilostazol—Urticaria—Mycophenolate mofetil—psoriasis	0.000102	0.000382	CcSEcCtD
Cilostazol—Headache—Mycophenolic acid—psoriasis	0.000102	0.000382	CcSEcCtD
Cilostazol—Decreased appetite—Hydrocortisone—psoriasis	0.000102	0.000381	CcSEcCtD
Cilostazol—Pharyngitis—Methotrexate—psoriasis	0.000102	0.00038	CcSEcCtD
Cilostazol—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000101	0.00038	CcSEcCtD
Cilostazol—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000101	0.00038	CcSEcCtD
Cilostazol—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000101	0.000378	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.0001	0.000376	CcSEcCtD
Cilostazol—Pain—Hydrocortisone—psoriasis	0.0001	0.000374	CcSEcCtD
Cilostazol—Oedema—Betamethasone—psoriasis	9.99e-05	0.000374	CcSEcCtD
Cilostazol—Oedema—Dexamethasone—psoriasis	9.99e-05	0.000374	CcSEcCtD
Cilostazol—Insomnia—Triamcinolone—psoriasis	9.95e-05	0.000373	CcSEcCtD
Cilostazol—Infection—Betamethasone—psoriasis	9.92e-05	0.000372	CcSEcCtD
Cilostazol—Infection—Dexamethasone—psoriasis	9.92e-05	0.000372	CcSEcCtD
Cilostazol—Ill-defined disorder—Prednisone—psoriasis	9.89e-05	0.00037	CcSEcCtD
Cilostazol—Paraesthesia—Triamcinolone—psoriasis	9.88e-05	0.00037	CcSEcCtD
Cilostazol—Feeling abnormal—Prednisolone—psoriasis	9.86e-05	0.000369	CcSEcCtD
Cilostazol—Anaemia—Prednisone—psoriasis	9.85e-05	0.000369	CcSEcCtD
Cilostazol—Shock—Betamethasone—psoriasis	9.83e-05	0.000368	CcSEcCtD
Cilostazol—Shock—Dexamethasone—psoriasis	9.83e-05	0.000368	CcSEcCtD
Cilostazol—Dyspnoea—Triamcinolone—psoriasis	9.81e-05	0.000368	CcSEcCtD
Cilostazol—Nervous system disorder—Betamethasone—psoriasis	9.79e-05	0.000367	CcSEcCtD
Cilostazol—Nervous system disorder—Dexamethasone—psoriasis	9.79e-05	0.000367	CcSEcCtD
Cilostazol—Thrombocytopenia—Dexamethasone—psoriasis	9.78e-05	0.000366	CcSEcCtD
Cilostazol—Thrombocytopenia—Betamethasone—psoriasis	9.78e-05	0.000366	CcSEcCtD
Cilostazol—Tachycardia—Betamethasone—psoriasis	9.75e-05	0.000365	CcSEcCtD
Cilostazol—Tachycardia—Dexamethasone—psoriasis	9.75e-05	0.000365	CcSEcCtD
Cilostazol—Dyspepsia—Triamcinolone—psoriasis	9.69e-05	0.000363	CcSEcCtD
Cilostazol—Erythema multiforme—Methotrexate—psoriasis	9.67e-05	0.000362	CcSEcCtD
Cilostazol—Nausea—Mycophenolic acid—psoriasis	9.66e-05	0.000362	CcSEcCtD
Cilostazol—Feeling abnormal—Hydrocortisone—psoriasis	9.63e-05	0.000361	CcSEcCtD
Cilostazol—Malaise—Prednisone—psoriasis	9.61e-05	0.00036	CcSEcCtD
Cilostazol—Vertigo—Prednisone—psoriasis	9.57e-05	0.000359	CcSEcCtD
Cilostazol—Gastrointestinal pain—Hydrocortisone—psoriasis	9.56e-05	0.000358	CcSEcCtD
Cilostazol—Syncope—Prednisone—psoriasis	9.56e-05	0.000358	CcSEcCtD
Cilostazol—Tinnitus—Methotrexate—psoriasis	9.54e-05	0.000357	CcSEcCtD
Cilostazol—Anorexia—Betamethasone—psoriasis	9.52e-05	0.000357	CcSEcCtD
Cilostazol—Anorexia—Dexamethasone—psoriasis	9.52e-05	0.000357	CcSEcCtD
Cilostazol—Urticaria—Prednisolone—psoriasis	9.51e-05	0.000356	CcSEcCtD
Cilostazol—Cardiac disorder—Methotrexate—psoriasis	9.49e-05	0.000356	CcSEcCtD
Cilostazol—Asthenia—Cyclosporine—psoriasis	9.44e-05	0.000354	CcSEcCtD
Cilostazol—PDE3A—Signaling by GPCR—HCAR2—psoriasis	9.42e-05	0.0068	CbGpPWpGaD
Cilostazol—Pain—Triamcinolone—psoriasis	9.41e-05	0.000353	CcSEcCtD
Cilostazol—Loss of consciousness—Prednisone—psoriasis	9.37e-05	0.000351	CcSEcCtD
Cilostazol—Hypotension—Dexamethasone—psoriasis	9.33e-05	0.00035	CcSEcCtD
Cilostazol—Hypotension—Betamethasone—psoriasis	9.33e-05	0.00035	CcSEcCtD
Cilostazol—CYP2C19—Biological oxidations—CYP2S1—psoriasis	9.32e-05	0.00672	CbGpPWpGaD
Cilostazol—Pruritus—Cyclosporine—psoriasis	9.31e-05	0.000349	CcSEcCtD
Cilostazol—Urticaria—Hydrocortisone—psoriasis	9.29e-05	0.000348	CcSEcCtD
Cilostazol—Angiopathy—Methotrexate—psoriasis	9.28e-05	0.000348	CcSEcCtD
Cilostazol—Body temperature increased—Hydrocortisone—psoriasis	9.24e-05	0.000346	CcSEcCtD
Cilostazol—Abdominal pain—Hydrocortisone—psoriasis	9.24e-05	0.000346	CcSEcCtD
Cilostazol—Mediastinal disorder—Methotrexate—psoriasis	9.22e-05	0.000345	CcSEcCtD
Cilostazol—Asthenia—Mycophenolate mofetil—psoriasis	9.21e-05	0.000345	CcSEcCtD
Cilostazol—Hypertension—Prednisone—psoriasis	9.2e-05	0.000345	CcSEcCtD
Cilostazol—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	9.19e-05	0.00663	CbGpPWpGaD
Cilostazol—Chills—Methotrexate—psoriasis	9.18e-05	0.000344	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Betamethasone—psoriasis	9.1e-05	0.000341	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Dexamethasone—psoriasis	9.1e-05	0.000341	CcSEcCtD
Cilostazol—Pruritus—Mycophenolate mofetil—psoriasis	9.08e-05	0.00034	CcSEcCtD
Cilostazol—Myalgia—Prednisone—psoriasis	9.07e-05	0.00034	CcSEcCtD
Cilostazol—Arthralgia—Prednisone—psoriasis	9.07e-05	0.00034	CcSEcCtD
Cilostazol—Feeling abnormal—Triamcinolone—psoriasis	9.07e-05	0.00034	CcSEcCtD
Cilostazol—Anxiety—Prednisone—psoriasis	9.04e-05	0.000339	CcSEcCtD
Cilostazol—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	9.03e-05	0.00652	CbGpPWpGaD
Cilostazol—Insomnia—Betamethasone—psoriasis	9.03e-05	0.000338	CcSEcCtD
Cilostazol—Insomnia—Dexamethasone—psoriasis	9.03e-05	0.000338	CcSEcCtD
Cilostazol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	9.01e-05	0.000338	CcSEcCtD
Cilostazol—Diarrhoea—Cyclosporine—psoriasis	9e-05	0.000337	CcSEcCtD
Cilostazol—Paraesthesia—Dexamethasone—psoriasis	8.97e-05	0.000336	CcSEcCtD
Cilostazol—Paraesthesia—Betamethasone—psoriasis	8.97e-05	0.000336	CcSEcCtD
Cilostazol—Discomfort—Prednisone—psoriasis	8.96e-05	0.000336	CcSEcCtD
Cilostazol—Dyspepsia—Betamethasone—psoriasis	8.79e-05	0.000329	CcSEcCtD
Cilostazol—Dyspepsia—Dexamethasone—psoriasis	8.79e-05	0.000329	CcSEcCtD
Cilostazol—Diarrhoea—Mycophenolate mofetil—psoriasis	8.78e-05	0.000329	CcSEcCtD
Cilostazol—Urticaria—Triamcinolone—psoriasis	8.74e-05	0.000328	CcSEcCtD
Cilostazol—Body temperature increased—Triamcinolone—psoriasis	8.7e-05	0.000326	CcSEcCtD
Cilostazol—Dizziness—Cyclosporine—psoriasis	8.7e-05	0.000326	CcSEcCtD
Cilostazol—Oedema—Prednisone—psoriasis	8.7e-05	0.000326	CcSEcCtD
Cilostazol—Decreased appetite—Betamethasone—psoriasis	8.68e-05	0.000325	CcSEcCtD
Cilostazol—Decreased appetite—Dexamethasone—psoriasis	8.68e-05	0.000325	CcSEcCtD
Cilostazol—Infection—Prednisone—psoriasis	8.64e-05	0.000324	CcSEcCtD
Cilostazol—Gastrointestinal disorder—Betamethasone—psoriasis	8.62e-05	0.000323	CcSEcCtD
Cilostazol—Gastrointestinal disorder—Dexamethasone—psoriasis	8.62e-05	0.000323	CcSEcCtD
Cilostazol—Back pain—Methotrexate—psoriasis	8.61e-05	0.000323	CcSEcCtD
Cilostazol—CYP2D6—Biological oxidations—CYP2S1—psoriasis	8.57e-05	0.00618	CbGpPWpGaD
Cilostazol—Shock—Prednisone—psoriasis	8.56e-05	0.000321	CcSEcCtD
Cilostazol—Pain—Betamethasone—psoriasis	8.54e-05	0.00032	CcSEcCtD
Cilostazol—Pain—Dexamethasone—psoriasis	8.54e-05	0.00032	CcSEcCtD
Cilostazol—Nervous system disorder—Prednisone—psoriasis	8.53e-05	0.00032	CcSEcCtD
Cilostazol—Tachycardia—Prednisone—psoriasis	8.49e-05	0.000318	CcSEcCtD
Cilostazol—Dizziness—Mycophenolate mofetil—psoriasis	8.48e-05	0.000318	CcSEcCtD
Cilostazol—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	8.45e-05	0.0061	CbGpPWpGaD
Cilostazol—Skin disorder—Prednisone—psoriasis	8.45e-05	0.000316	CcSEcCtD
Cilostazol—Asthenia—Hydrocortisone—psoriasis	8.39e-05	0.000314	CcSEcCtD
Cilostazol—Vomiting—Cyclosporine—psoriasis	8.36e-05	0.000313	CcSEcCtD
Cilostazol—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	8.31e-05	0.00599	CbGpPWpGaD
Cilostazol—Rash—Cyclosporine—psoriasis	8.29e-05	0.000311	CcSEcCtD
Cilostazol—Anorexia—Prednisone—psoriasis	8.29e-05	0.000311	CcSEcCtD
Cilostazol—Dermatitis—Cyclosporine—psoriasis	8.29e-05	0.00031	CcSEcCtD
Cilostazol—Pruritus—Hydrocortisone—psoriasis	8.27e-05	0.00031	CcSEcCtD
Cilostazol—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	8.26e-05	0.00596	CbGpPWpGaD
Cilostazol—Ill-defined disorder—Methotrexate—psoriasis	8.26e-05	0.00031	CcSEcCtD
Cilostazol—Headache—Cyclosporine—psoriasis	8.24e-05	0.000309	CcSEcCtD
Cilostazol—Anaemia—Methotrexate—psoriasis	8.23e-05	0.000308	CcSEcCtD
Cilostazol—Feeling abnormal—Betamethasone—psoriasis	8.23e-05	0.000308	CcSEcCtD
Cilostazol—Feeling abnormal—Dexamethasone—psoriasis	8.23e-05	0.000308	CcSEcCtD
Cilostazol—Gastrointestinal pain—Dexamethasone—psoriasis	8.17e-05	0.000306	CcSEcCtD
Cilostazol—Gastrointestinal pain—Betamethasone—psoriasis	8.17e-05	0.000306	CcSEcCtD
Cilostazol—Vomiting—Mycophenolate mofetil—psoriasis	8.16e-05	0.000306	CcSEcCtD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	8.09e-05	0.00584	CbGpPWpGaD
Cilostazol—Rash—Mycophenolate mofetil—psoriasis	8.09e-05	0.000303	CcSEcCtD
Cilostazol—Dermatitis—Mycophenolate mofetil—psoriasis	8.08e-05	0.000303	CcSEcCtD
Cilostazol—Headache—Mycophenolate mofetil—psoriasis	8.04e-05	0.000301	CcSEcCtD
Cilostazol—Malaise—Methotrexate—psoriasis	8.03e-05	0.000301	CcSEcCtD
Cilostazol—Vertigo—Methotrexate—psoriasis	8e-05	0.0003	CcSEcCtD
Cilostazol—Diarrhoea—Hydrocortisone—psoriasis	8e-05	0.0003	CcSEcCtD
Cilostazol—Leukopenia—Methotrexate—psoriasis	7.97e-05	0.000299	CcSEcCtD
Cilostazol—Urticaria—Dexamethasone—psoriasis	7.93e-05	0.000297	CcSEcCtD
Cilostazol—Urticaria—Betamethasone—psoriasis	7.93e-05	0.000297	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Prednisone—psoriasis	7.92e-05	0.000297	CcSEcCtD
Cilostazol—Dizziness—Prednisolone—psoriasis	7.91e-05	0.000296	CcSEcCtD
Cilostazol—Asthenia—Triamcinolone—psoriasis	7.9e-05	0.000296	CcSEcCtD
Cilostazol—Abdominal pain—Dexamethasone—psoriasis	7.89e-05	0.000296	CcSEcCtD
Cilostazol—Abdominal pain—Betamethasone—psoriasis	7.89e-05	0.000296	CcSEcCtD
Cilostazol—Body temperature increased—Dexamethasone—psoriasis	7.89e-05	0.000296	CcSEcCtD
Cilostazol—Body temperature increased—Betamethasone—psoriasis	7.89e-05	0.000296	CcSEcCtD
Cilostazol—PDE3A—Hemostasis—ITGAL—psoriasis	7.87e-05	0.00568	CbGpPWpGaD
Cilostazol—Insomnia—Prednisone—psoriasis	7.87e-05	0.000295	CcSEcCtD
Cilostazol—Nausea—Cyclosporine—psoriasis	7.81e-05	0.000293	CcSEcCtD
Cilostazol—Paraesthesia—Prednisone—psoriasis	7.81e-05	0.000293	CcSEcCtD
Cilostazol—Pruritus—Triamcinolone—psoriasis	7.79e-05	0.000292	CcSEcCtD
Cilostazol—Cough—Methotrexate—psoriasis	7.77e-05	0.000291	CcSEcCtD
Cilostazol—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.74e-05	0.00559	CbGpPWpGaD
Cilostazol—Dizziness—Hydrocortisone—psoriasis	7.73e-05	0.00029	CcSEcCtD
Cilostazol—Dyspepsia—Prednisone—psoriasis	7.66e-05	0.000287	CcSEcCtD
Cilostazol—Nausea—Mycophenolate mofetil—psoriasis	7.62e-05	0.000285	CcSEcCtD
Cilostazol—Chest pain—Methotrexate—psoriasis	7.58e-05	0.000284	CcSEcCtD
Cilostazol—Arthralgia—Methotrexate—psoriasis	7.58e-05	0.000284	CcSEcCtD
Cilostazol—Myalgia—Methotrexate—psoriasis	7.58e-05	0.000284	CcSEcCtD
Cilostazol—Decreased appetite—Prednisone—psoriasis	7.56e-05	0.000283	CcSEcCtD
Cilostazol—Rash—Prednisolone—psoriasis	7.55e-05	0.000283	CcSEcCtD
Cilostazol—Dermatitis—Prednisolone—psoriasis	7.54e-05	0.000282	CcSEcCtD
Cilostazol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	7.53e-05	0.000282	CcSEcCtD
Cilostazol—Headache—Prednisolone—psoriasis	7.5e-05	0.000281	CcSEcCtD
Cilostazol—Discomfort—Methotrexate—psoriasis	7.49e-05	0.000281	CcSEcCtD
Cilostazol—Vomiting—Hydrocortisone—psoriasis	7.43e-05	0.000278	CcSEcCtD
Cilostazol—Rash—Hydrocortisone—psoriasis	7.37e-05	0.000276	CcSEcCtD
Cilostazol—Dermatitis—Hydrocortisone—psoriasis	7.36e-05	0.000276	CcSEcCtD
Cilostazol—Headache—Hydrocortisone—psoriasis	7.32e-05	0.000274	CcSEcCtD
Cilostazol—Dizziness—Triamcinolone—psoriasis	7.28e-05	0.000273	CcSEcCtD
Cilostazol—CYP1A2—Biological oxidations—CYP2S1—psoriasis	7.26e-05	0.00524	CbGpPWpGaD
Cilostazol—Infection—Methotrexate—psoriasis	7.22e-05	0.000271	CcSEcCtD
Cilostazol—Feeling abnormal—Prednisone—psoriasis	7.17e-05	0.000268	CcSEcCtD
Cilostazol—Asthenia—Betamethasone—psoriasis	7.17e-05	0.000268	CcSEcCtD
Cilostazol—Asthenia—Dexamethasone—psoriasis	7.17e-05	0.000268	CcSEcCtD
Cilostazol—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	7.16e-05	0.00516	CbGpPWpGaD
Cilostazol—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	7.15e-05	0.00516	CbGpPWpGaD
Cilostazol—Nervous system disorder—Methotrexate—psoriasis	7.13e-05	0.000267	CcSEcCtD
Cilostazol—Thrombocytopenia—Methotrexate—psoriasis	7.12e-05	0.000267	CcSEcCtD
Cilostazol—Gastrointestinal pain—Prednisone—psoriasis	7.11e-05	0.000266	CcSEcCtD
Cilostazol—Nausea—Prednisolone—psoriasis	7.11e-05	0.000266	CcSEcCtD
Cilostazol—Pruritus—Dexamethasone—psoriasis	7.07e-05	0.000265	CcSEcCtD
Cilostazol—Pruritus—Betamethasone—psoriasis	7.07e-05	0.000265	CcSEcCtD
Cilostazol—Skin disorder—Methotrexate—psoriasis	7.06e-05	0.000264	CcSEcCtD
Cilostazol—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	7.04e-05	0.00508	CbGpPWpGaD
Cilostazol—Vomiting—Triamcinolone—psoriasis	7e-05	0.000262	CcSEcCtD
Cilostazol—Nausea—Hydrocortisone—psoriasis	6.94e-05	0.00026	CcSEcCtD
Cilostazol—Rash—Triamcinolone—psoriasis	6.94e-05	0.00026	CcSEcCtD
Cilostazol—Dermatitis—Triamcinolone—psoriasis	6.93e-05	0.00026	CcSEcCtD
Cilostazol—Anorexia—Methotrexate—psoriasis	6.93e-05	0.00026	CcSEcCtD
Cilostazol—Urticaria—Prednisone—psoriasis	6.91e-05	0.000259	CcSEcCtD
Cilostazol—Headache—Triamcinolone—psoriasis	6.9e-05	0.000258	CcSEcCtD
Cilostazol—Body temperature increased—Prednisone—psoriasis	6.88e-05	0.000258	CcSEcCtD
Cilostazol—Abdominal pain—Prednisone—psoriasis	6.88e-05	0.000258	CcSEcCtD
Cilostazol—Diarrhoea—Betamethasone—psoriasis	6.83e-05	0.000256	CcSEcCtD
Cilostazol—Diarrhoea—Dexamethasone—psoriasis	6.83e-05	0.000256	CcSEcCtD
Cilostazol—Hypotension—Methotrexate—psoriasis	6.79e-05	0.000254	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Methotrexate—psoriasis	6.62e-05	0.000248	CcSEcCtD
Cilostazol—Dizziness—Dexamethasone—psoriasis	6.6e-05	0.000247	CcSEcCtD
Cilostazol—Dizziness—Betamethasone—psoriasis	6.6e-05	0.000247	CcSEcCtD
Cilostazol—Insomnia—Methotrexate—psoriasis	6.57e-05	0.000246	CcSEcCtD
Cilostazol—Nausea—Triamcinolone—psoriasis	6.54e-05	0.000245	CcSEcCtD
Cilostazol—Paraesthesia—Methotrexate—psoriasis	6.53e-05	0.000244	CcSEcCtD
Cilostazol—Dyspnoea—Methotrexate—psoriasis	6.48e-05	0.000243	CcSEcCtD
Cilostazol—Dyspepsia—Methotrexate—psoriasis	6.4e-05	0.00024	CcSEcCtD
Cilostazol—Vomiting—Betamethasone—psoriasis	6.35e-05	0.000238	CcSEcCtD
Cilostazol—Vomiting—Dexamethasone—psoriasis	6.35e-05	0.000238	CcSEcCtD
Cilostazol—Decreased appetite—Methotrexate—psoriasis	6.32e-05	0.000237	CcSEcCtD
Cilostazol—Rash—Dexamethasone—psoriasis	6.3e-05	0.000236	CcSEcCtD
Cilostazol—Rash—Betamethasone—psoriasis	6.3e-05	0.000236	CcSEcCtD
Cilostazol—Dermatitis—Betamethasone—psoriasis	6.29e-05	0.000236	CcSEcCtD
Cilostazol—Dermatitis—Dexamethasone—psoriasis	6.29e-05	0.000236	CcSEcCtD
Cilostazol—Gastrointestinal disorder—Methotrexate—psoriasis	6.28e-05	0.000235	CcSEcCtD
Cilostazol—CYP1A2—Tryptophan metabolism—CAT—psoriasis	6.26e-05	0.00452	CbGpPWpGaD
Cilostazol—Headache—Betamethasone—psoriasis	6.26e-05	0.000234	CcSEcCtD
Cilostazol—Headache—Dexamethasone—psoriasis	6.26e-05	0.000234	CcSEcCtD
Cilostazol—Asthenia—Prednisone—psoriasis	6.24e-05	0.000234	CcSEcCtD
Cilostazol—Pain—Methotrexate—psoriasis	6.22e-05	0.000233	CcSEcCtD
Cilostazol—Pruritus—Prednisone—psoriasis	6.15e-05	0.000231	CcSEcCtD
Cilostazol—Feeling abnormal—Methotrexate—psoriasis	5.99e-05	0.000224	CcSEcCtD
Cilostazol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.98e-05	0.00431	CbGpPWpGaD
Cilostazol—Diarrhoea—Prednisone—psoriasis	5.95e-05	0.000223	CcSEcCtD
Cilostazol—Gastrointestinal pain—Methotrexate—psoriasis	5.94e-05	0.000223	CcSEcCtD
Cilostazol—Nausea—Dexamethasone—psoriasis	5.93e-05	0.000222	CcSEcCtD
Cilostazol—Nausea—Betamethasone—psoriasis	5.93e-05	0.000222	CcSEcCtD
Cilostazol—Urticaria—Methotrexate—psoriasis	5.77e-05	0.000216	CcSEcCtD
Cilostazol—Dizziness—Prednisone—psoriasis	5.75e-05	0.000215	CcSEcCtD
Cilostazol—Abdominal pain—Methotrexate—psoriasis	5.75e-05	0.000215	CcSEcCtD
Cilostazol—Body temperature increased—Methotrexate—psoriasis	5.75e-05	0.000215	CcSEcCtD
Cilostazol—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.6e-05	0.00404	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—HCAR2—psoriasis	5.57e-05	0.00401	CbGpPWpGaD
Cilostazol—Vomiting—Prednisone—psoriasis	5.53e-05	0.000207	CcSEcCtD
Cilostazol—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.53e-05	0.00399	CbGpPWpGaD
Cilostazol—Rash—Prednisone—psoriasis	5.48e-05	0.000205	CcSEcCtD
Cilostazol—Dermatitis—Prednisone—psoriasis	5.48e-05	0.000205	CcSEcCtD
Cilostazol—Headache—Prednisone—psoriasis	5.45e-05	0.000204	CcSEcCtD
Cilostazol—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.4e-05	0.00389	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CCL20—psoriasis	5.39e-05	0.00389	CbGpPWpGaD
Cilostazol—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	5.37e-05	0.00388	CbGpPWpGaD
Cilostazol—Asthenia—Methotrexate—psoriasis	5.21e-05	0.000195	CcSEcCtD
Cilostazol—Nausea—Prednisone—psoriasis	5.17e-05	0.000194	CcSEcCtD
Cilostazol—Pruritus—Methotrexate—psoriasis	5.14e-05	0.000193	CcSEcCtD
Cilostazol—Diarrhoea—Methotrexate—psoriasis	4.97e-05	0.000186	CcSEcCtD
Cilostazol—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	4.94e-05	0.00356	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CCL20—psoriasis	4.89e-05	0.00353	CbGpPWpGaD
Cilostazol—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4.83e-05	0.00349	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—TAGAP—psoriasis	4.83e-05	0.00348	CbGpPWpGaD
Cilostazol—Dizziness—Methotrexate—psoriasis	4.81e-05	0.00018	CcSEcCtD
Cilostazol—Vomiting—Methotrexate—psoriasis	4.62e-05	0.000173	CcSEcCtD
Cilostazol—Rash—Methotrexate—psoriasis	4.58e-05	0.000172	CcSEcCtD
Cilostazol—Dermatitis—Methotrexate—psoriasis	4.58e-05	0.000172	CcSEcCtD
Cilostazol—Headache—Methotrexate—psoriasis	4.55e-05	0.000171	CcSEcCtD
Cilostazol—Nausea—Methotrexate—psoriasis	4.32e-05	0.000162	CcSEcCtD
Cilostazol—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	4.19e-05	0.00302	CbGpPWpGaD
Cilostazol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.17e-05	0.00301	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.48e-05	0.00251	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—NDUFA5—psoriasis	3.35e-05	0.00242	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—NOS2—psoriasis	3.23e-05	0.00233	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.01e-05	0.00217	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.89e-05	0.00209	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CCL20—psoriasis	2.89e-05	0.00209	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—CYP2S1—psoriasis	2.85e-05	0.00206	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.63e-05	0.00189	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—NDUFA5—psoriasis	2.42e-05	0.00175	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.25e-05	0.00162	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.25e-05	0.00162	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—CYP2S1—psoriasis	2.06e-05	0.00149	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—NDUFA5—psoriasis	1.87e-05	0.00135	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—VEGFA—psoriasis	1.87e-05	0.00135	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.75e-05	0.00126	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—NDUFA5—psoriasis	1.72e-05	0.00124	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—CYP2S1—psoriasis	1.59e-05	0.00115	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—SOCS1—psoriasis	1.59e-05	0.00115	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—TYK2—psoriasis	1.52e-05	0.00109	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—CYP2S1—psoriasis	1.47e-05	0.00106	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—NDUFA5—psoriasis	1.46e-05	0.00105	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CXCL8—psoriasis	1.46e-05	0.00105	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—TP53—psoriasis	1.41e-05	0.00102	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—CARM1—psoriasis	1.39e-05	0.001	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.36e-05	0.000982	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CXCL8—psoriasis	1.32e-05	0.000953	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—CYP2S1—psoriasis	1.24e-05	0.000896	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—APOE—psoriasis	1.17e-05	0.000847	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—LEP—psoriasis	1.17e-05	0.000847	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—NDUFA5—psoriasis	1.13e-05	0.000813	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—NFKBIA—psoriasis	1.09e-05	0.00079	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—CARM1—psoriasis	1.01e-05	0.000726	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—CYP2S1—psoriasis	9.58e-06	0.000691	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—TYK2—psoriasis	8.97e-06	0.000647	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—CAT—psoriasis	8.56e-06	0.000618	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.35e-06	0.000602	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CXCL8—psoriasis	7.81e-06	0.000563	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—CARM1—psoriasis	7.78e-06	0.000561	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—IL6—psoriasis	7.42e-06	0.000535	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.27e-06	0.000525	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—JUN—psoriasis	7.26e-06	0.000523	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—CARM1—psoriasis	7.16e-06	0.000516	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—NFKB1—psoriasis	6.99e-06	0.000504	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—APOE—psoriasis	6.65e-06	0.00048	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.51e-06	0.000469	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—VEGFA—psoriasis	6.34e-06	0.000457	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—STAT3—psoriasis	6.28e-06	0.000453	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—CAT—psoriasis	6.19e-06	0.000447	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—CARM1—psoriasis	6.06e-06	0.000437	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—PPARG—psoriasis	5.8e-06	0.000418	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.67e-06	0.000409	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—APOE—psoriasis	4.81e-06	0.000347	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—TP53—psoriasis	4.79e-06	0.000346	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—CAT—psoriasis	4.79e-06	0.000345	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—CARM1—psoriasis	4.68e-06	0.000338	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—CAT—psoriasis	4.4e-06	0.000318	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—IL6—psoriasis	4.39e-06	0.000316	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—PPARG—psoriasis	4.19e-06	0.000302	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—CAT—psoriasis	3.73e-06	0.000269	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—APOE—psoriasis	3.72e-06	0.000268	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—APOE—psoriasis	3.42e-06	0.000247	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—PPARG—psoriasis	3.24e-06	0.000234	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—PPARG—psoriasis	2.98e-06	0.000215	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—APOE—psoriasis	2.9e-06	0.000209	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—CAT—psoriasis	2.88e-06	0.000208	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—PPARG—psoriasis	2.52e-06	0.000182	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—APOE—psoriasis	2.24e-06	0.000161	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—PPARG—psoriasis	1.95e-06	0.000141	CbGpPWpGaD
